NCT02981446View on ClinicalTrials.gov

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

PHASE3CompletedINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Open Angle Glaucoma or Ocular Hypertension
Interventions
DRUG

DE-117

DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.

DRUG

Latanoprost ophthalmic solution

Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.

Trial Locations (1)

Unknown

Singapore

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT02981446 - A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT | Biotech Hunter | Biotech Hunter